Pregabalin Capsule
Product Images NDC 71205-298

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71205-298). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

71205-298-60 (Pregabalin 75mg 1000)

The label for Pregabalin 75 mg capsules, packaged in a bottle of 60 capsules by Proficient Rx LP. The label states the product is prescription-only with a Schedule C-V designation. Capsules are described as red and white opaque hard gelatin, imprinted with "LA" on the cap and "43" on the body, containing white to off-white granular powder. Manufacturer is Laurus Labs Limited, India.*

FDA Label Image

Pregabalinchemistrystructure (Pregabalin Chem Structure)

Chemical structure of Pregabalin showing its molecular arrangement with amino and carboxyl functional groups, consistent with the active ingredient in the PREGABALIN 75 mg capsule by Proficient Rx LP.*

FDA Label Image

Pregabalin-equation (Pregabalin Equation)

A mathematical formula calculating creatinine clearance (CLCr) based on age in years, weight in kilograms, serum creatinine in mg/dL, and a factor for female patients. This formula is likely related to dosing or kidney function assessment.*

FDA Label Image

Pregabalinfig1 (Pregabalin Fig 01)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline for Pregabalin at doses of 25 mg, 100 mg, and 200 mg taken three times a day, compared to placebo. The graph shows trends in patient improvement across different pain improvement thresholds.*

FDA Label Image

Pregabalinfig2 (Pregabalin Fig 02)

A line graph comparing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin 100 mg three times a day and placebo. The graph shows the treatment effect over a range of pain improvement percentages, with Pregabalin demonstrating higher patient improvement rates than placebo across the scale.*

FDA Label Image

Pregabalinfig3 (Pregabalin Fig 03)

A line graph showing percent of patients improved versus percent improvement in pain from baseline for Pregabalin at doses of 75 mg, 150 mg, and 300 mg taken twice a day, compared to placebo. The graph displays a descending trend for all groups as pain improvement increases.*

FDA Label Image

Pregabalinfig4 (Pregabalin Fig 04)

A line graph showing percent improvement in pain from baseline plotted against percent of patients improved. The graph compares three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and Placebo, with the Pregabalin 200 mg group showing higher percentages of patient improvement than the others.*

FDA Label Image

Pregabalinfig5 (Pregabalin Fig 05)

A line graph depicting percent improvement in pain from baseline on the x-axis and percent of patients improved on the y-axis. It compares the effects of pregabalin 50 mg three times a day, pregabalin 100 mg three times a day, and placebo, showing the relative percentages of patients experiencing various degrees of pain improvement.*

FDA Label Image

Pregabalinfig6 (Pregabalin Fig 06)

A bar chart comparing responder rates (%) across different dosages and placebo in two studies labeled E1 and E3 for Pregabalin. The x-axis shows dosing groups including placebo, 50 mg, 80 mg, 30 mg, and 600 mg per day, with participant numbers noted. The y-axis represents responder rates from 0% to 60%. Study E1 shows increasing response rates with higher doses, peaking at 600 mg/day. Study E3 compares placebo with 600 mg/day given either 5 or 10 times daily, showing higher responder rates for 600 mg doses.*

FDA Label Image

Pregabalinfig7 (Pregabalin Fig 07)

A line graph depicting seizure reduction as median percent change from baseline versus daily dose in mg. The graph shows data points from four studies labeled E1 BD, E2 TID, E3 BD, and E3 TID, with dose ranging from 0 to 600 mg/day. Significant p-values are indicated near data points, showing seizure reduction increases with dose, and placebo corresponds to 0 dose.*

FDA Label Image

Pregabalinfig8 (Pregabalin Fig 08)

A line graph comparing the percent of patients improved versus the percent improvement in pain from baseline for pregabalin at daily doses of 600 mg, 450 mg, 300 mg, and placebo. The x-axis represents percent improvement in pain from baseline, and the y-axis shows percent of patients improved, with four lines depicting the different treatment groups.*

FDA Label Image

Pregabalinfig9 (Pregabalin Fig 09)

A Kaplan-Meier survival curve graph comparing pregabalin and placebo groups over 180 days. The y-axis represents the estimated percentage of subjects without LTR (loss to response), and the x-axis shows days. The graph shows Pregabalin with higher survival estimates than placebo throughout the period.*

FDA Label Image

Pregabalinfig10 (Pregabalin Fig 10)

A line graph showing the percentage of subjects improved over time from baseline to Week 12 BOCF comparing Pregabalin and placebo. The x-axis represents the percent improved from baseline to Week 12, and the y-axis shows the percent of subjects improved. Pregabalin demonstrates a higher percentage of subjects improved compared to placebo across the range.*

FDA Label Image

Pregabalinfig11 (Pregabalin Fig 11)

A line graph comparing the percent of subjects improved over varying percentages improved from baseline to week 16 BOCF. The graph features two lines: one solid line representing Pregabalin and one dashed line representing Placebo, showing a higher percentage of subjects improved with Pregabalin across the range.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.